Company intelligence / Profile preview

IROC Innocross

Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

IROC Innocross was the first company to commercialize a corneal collagen cross-linking device (UV-X) for the treatment of keratoconus and other corneal disorders, with global commercial adoption prior to its acquisition.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

MDP Solutions (supplier)Solnovis (supplier)

Beyond the preview

Go deeper on IROC Innocross.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IROC Innocross.

Explore the full profile